TD Cowen on DexCom (DXCM): ' G7 Issues Are Mostly Resolved, Limiting Share Shifts'

TD Cowen analyst Joshua Jennings reiterated a Buy rating and $100.00 price target on DexCom (NASDAQ: DXCM).

The analyst commented: "G7 Issues Are Mostly Resolved, Limiting Share Shifts and Brand Damage; The KOL we spoke with on Monday said that G7's deployment and accuracy issues from earlier this year have now mostly resolved. This view aligns with opinions we have heard from other experts and with remarks made by DXCM in recent weeks. The KOL reported little share movement in response to G7's challenges and expects little going forward. We continue to think DXCM is largely past its G7 problems."

For an analyst ratings summary and ratings history on DexCom click here. For more ratings news on DexCom click here.

Shares of DexCom closed at $67.50 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Phillips 66, Marathon Merger Talks Collapsed - Semafor
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy